Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

[1]  J. Cleveland,et al.  Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.

[2]  V. Rotter,et al.  Mutant p53 protein expression interferes with p53-independent apoptotic pathways , 1998, Oncogene.

[3]  S. Deb,et al.  `Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain , 1998, Oncogene.

[4]  K. Aldape,et al.  An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Prendergast,et al.  The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.

[6]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[7]  M. Oren,et al.  p53; from inductive signal to cellular effect. , 1997, Current opinion in genetics & development.

[8]  Peter A. Jones,et al.  p53 and treatment of bladder cancer , 1997, Nature.

[9]  G. Thomas,et al.  P53 gene alterations in human tumors: perspectives for cancer control. , 1997, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[10]  P. Chumakov,et al.  Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells. , 1997, Oncology research.

[11]  A. Levine,et al.  Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Deb,et al.  Transcriptional activation of the human epidermal growth factor receptor promoter by human p53 , 1996, Molecular and cellular biology.

[13]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[14]  N. Bleehen,et al.  Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. , 1996, British Journal of Cancer.

[15]  S. Lowe,et al.  Cancer therapy and p53. , 1995, Current opinion in oncology.

[16]  E. Dmitrovsky,et al.  Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. , 1995, Cancer research.

[17]  J. Lotem,et al.  A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[19]  E. Shaulian,et al.  Induction of apoptosis in HeLa cells by trans-activation-deficient p53. , 1995, Genes & development.

[20]  E. Hovig,et al.  TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains , 1995, Genes, chromosomes & cancer.

[21]  Z. Darżynkiewicz.  Apoptosis in anititumor strategies: Modulation of cell cycle or differentiation , 1995, Journal of cellular biochemistry.

[22]  T. Powles,et al.  p53 protein overexpression and chemosensitivity in breast cancer , 1995, The Lancet.

[23]  G. Ebers,et al.  Ondansetron for intractable vertigo complicating acute brainstem disorders , 1995, The Lancet.

[24]  J Milner,et al.  Flexibility: the key to p53 function? , 1995, Trends in biochemical sciences.

[25]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[26]  E. Newcomb,et al.  p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression , 1993 .

[27]  A. Fornace,et al.  Induction of Cellular p53 Activity by DNA-Damaging Agents and Growth Arrest , 1993, Molecular and cellular biology.

[28]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[29]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[30]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[31]  M. Subler,et al.  Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells , 1992, Journal of virology.

[32]  I. Pastan,et al.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. , 1992, Science.

[33]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[34]  O. Halevy,et al.  p53 Mutations: Gains or losses? , 1991, Journal of cellular biochemistry.

[35]  V. Rotter,et al.  Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene , 1984, Cell.